ASH 2025 | Choosing between imatinib and nilotinib in CML
In this video, Weiming Li, MD, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, discusses the findings of a real-world multicenter study that found comparable treatment-free remission (TFR) outcomes in patients with chronic myeloid leukemia (CML) treated with imatinib versus nilotinib. Dr Li notes that this information can aid clinicians in selecting between these two tyrosine kinase inhibitors (TKIs) when managing patients with the disease. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In my presentation, we got the main findings that Imatinib has a similar TFR rate as Nilotinib and that dose reductions before TKI discontinuation did not affect the TFR rate. So we can guide the doctors and the patients to select these two drugs, because Imatinib is safer than Nilotinib. But before we knew the patients and the doctors think that Imatinib is the first generation TKI and Nilotinib is the second generation TKI and it’s more potent than Imatinib...
In my presentation, we got the main findings that Imatinib has a similar TFR rate as Nilotinib and that dose reductions before TKI discontinuation did not affect the TFR rate. So we can guide the doctors and the patients to select these two drugs, because Imatinib is safer than Nilotinib. But before we knew the patients and the doctors think that Imatinib is the first generation TKI and Nilotinib is the second generation TKI and it’s more potent than Imatinib. And in general, the doctors believe that the second generation may have a higher TFR. But now we prove that the first generation has a similar TFR, so we can choose Imatinib. It’s a safer drug for the patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
